A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers
NCT01943864
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
20
Enrollment
INDUSTRY
Sponsor class
Conditions
Cancer
Interventions
DRUG:
Trametinib (single tablet)
DRUG:
Trametinib (Multiple tablet)
Sponsor
GlaxoSmithKline